Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 63, Issue 3, 2019, Pages

  Wilson, William R ^a   Kline, Ellen G ^b   Jones, Chelsea E ^b   Morder, Kristin T ^b   Mettus, Roberta T ^b   Doi, Yohei ^b   Nguyen, M Hong ^b,c   Clancy, Cornelius J ^b,d   Shields, Ryan K ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ceftazidime avibactam; CRE; Disk diffusion; Gradient strip; KPC; Meropenem vaborbactam; Porin

Indexed keywords

ALANINE; ASPARTIC ACID; AVIBACTAM PLUS CEFTAZIDIME; CARBAPENEMASE; GLYCINE; MEROPENEM PLUS VABORBACTAM; PORIN; THREONINE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA-LACTAMASE KPC-1; BORONIC ACID DERIVATIVE; CEFTAZIDIME; MEROPENEM; MEROPENEM AND VABORBACTAM; OMPK36 PROTEIN, KLEBSIELLA PNEUMONIAE; SINGLE HETEROCYCLIC RINGS;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; DISK DIFFUSION; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GENETIC VARIABILITY; GENOTYPE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG COMBINATIONS; ESCHERICHIA COLI; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; KLEBSIELLA PNEUMONIAE; MEROPENEM; PORINS;

EID: 85062285910     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02048-18     Document Type: Article

References (34)

1. Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant Enterobacteriaceae: epidemiology, and prevention. Clin Infect Dis 53: 60–67. https://doi.org/10.1093/cid/cir202.
2. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. 2015. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2:ofv050. https://doi.org/10.1093/ofid/ofv050.
3. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. 2017. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61:e00883-17. https://doi.org/10.1128/AAC.00883-17.
4. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG, Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership Group. 2018. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 66:163–171. https://doi.org/10.1093/cid/cix783.
5. Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, Tascini C, Parruti G, Pallotto C, Sica S, Concia E, Cultrera R, De Pascale G, Capone A, Antinori S, Corcione S, Righi E, Losito AR, Digaetano M, Amadori F, Giacobbe DR, Ceccarelli G, Mazza E, Raffaelli F, Spanu T, Cauda R, Viale P. 2019. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by KPC-producing Klebsiella pneumoniae. Clin Infect Dis 68:355–364. https://doi.org/10.1093/cid/ciy492.
6. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618. https://doi.org/10.1093/cid/ciw636.
7. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
8. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature. Open Forum Infect Dis 4:ofx101. https://doi.org/10.1093/ofid/ofx101.
9. Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. 2018. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 62:e02497-17. https://doi.org/10.1128/AAC.02497-17.
10. Both A, Buttner H, Huang J, Perbandt M, Belmar Campos C, Christner M, Maurer FP, Kluge S, Konig C, Aepfelbacher M, Wichmann D, Rohde H. 2017. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother 72:2483–2488. https://doi.org/10.1093/jac/dkx179.
11. KPC-2-harboring Klebsiella pneumoniae ST307. Antimicrob Agents Chemother 62:e02101-17. https://doi.org/10.1128/AAC.02101-17.
12. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:5324–5330. https://doi.org/10.1128/AAC.00678-15.
13. Barnes MD, Winkler ML, Taracila MA, Page MG, Desarbre E, Kreiswirth BN, Shields RK, Nguyen MH, Clancy C, Spellberg B, Papp-Wallace KM, Bonomo RA. 2017. Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from beta-lactamase protein engineering. mBio 8:e00528-17. https://doi.org/10 .1128/mBio.00528-17.
14. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. 2017. In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 61:e00079-17. https://doi.org/10.1128/AAC.00079-17.
15. KPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum beta-lactamases. Antimicrob Agents Chemother 61:e02534-16. https://doi.org/10.1128/AAC.02534-16.
16. Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN. 2017. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 61:e01443-17. https://doi.org/10.1128/AAC.01443-17.
17. van Duin D, Doi Y. 2017. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 8:460–469. https://doi.org/10.1080/21505594.2016.1222343.
18. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. 2018. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 62: e01904-17. https://doi.org/10.1128/AAC.1904-17.
19. Hong JH, Clancy CJ, Cheng S, Shields RK, Chen L, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother 57:2147–2153. https://doi.org/10.1128/AAC.02411-12.
20. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 57:5258–5265. https://doi.org/10.1128/AAC.01069-13.
21. Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH. 2015. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 59:5793–5797. https://doi.org/10.1128/AAC.00548-15.
22. Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00642 -17. https://doi.org/10.1128/AAC.00642-17.
23. Clancy CJ, Hao B, Shields RK, Chen L, Perlin DS, Kreiswirth BN, Nguyen MH. 2014. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob Agents Chemother 58:3521–3525. https://doi.org/10.1128/AAC.01949-13.
24. Shields RK, Nguyen MH, Potoski BA, Press EG, Chen L, Kreiswirth BN, Clarke LG, Eschenauer GA, Clancy CJ. 2015. Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. Antimicrob Agents Chemother 59:1797–1801. https://doi.org/10.1128/AAC.03894-14.
25. Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. 2018. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance pro-gramme. Int J Antimicrob Agents 52:144–150. https://doi.org/10.1016/j.ijantimicag.2018.02.021.
26. Centers for Disease Control and Prevention. 2018. Healthcare-associated infections (HAIs): tracking CRE. https://www.cdc.gov/hai/organisms/cre/trackingcre.html. Accessed 14 September 2018.
27. Shields RK, Clancy CJ, Pasculle AW, Press EG, Haidar G, Hao B, Chen L, Kreiswirth BN, Nguyen MH. 2018. Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 56:e001093-17. https://doi.org/10.1128/JCM.01093-17.
28. KPC) variants. J Clin Microbiol 49:579–585. https://doi.org/10.1128/JCM.01588-10.
29. Chen L, Chavda KD, Mediavilla JR, Zhao Y, Fraimow HS, Jenkins SG, Levi MH, Hong T, Rojtman AD, Ginocchio CC, Bonomo RA, Kreiswirth BN. 2012. Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone. Antimicrob Agents Chemother 56:3444–3447. https://doi.org/10.1128/AAC.00316-12.
30. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M. 2013. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13: 2619–2633. https://doi.org/10.1111/ajt.12424.
31. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Approved standard M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
32. Forest Pharmaceuticals, Inc. 2016. Avycaz (ceftazidime-avibactam). Prescribing information. Forest Pharmaceuticals, Inc, Cincinnati, Ohio.
33. Melinta Therapeutics, Inc. 2017. Vabomere (meropenem-vaborbactam). Prescribing information. Melinta Therapeutics, Inc, Lincolnshire, IL.
34. Patel JB, Sharp S, Novak-Weekley S. 2013. Verification of antimicrobial susceptibility testing methods: a practical approach. Clin Microbiol Newsl 35:103–109. https://doi.org/10.1016/j.clinmicnews.2013.06.001.